Use of complementary and alternative therapies in HIV-infected patients.
The use of complementary and alternative medicine (CAM) therapies is widespread in many chronic illnesses, including human immunodeficiency virus (HIV) infection. The objective of this study was to determine the impact of increasingly effective antiretroviral therapy on the use of CAM in an HIV-positive patient population. A written survey was given to 191 HIV-positive outpatients. Participation was voluntary and anonymous. One hundred twenty-eight patients (67%) used CAM at some time to control HIV and 76 (40%) of the patients were currently using CAM. The major forms of CAM used were exercise (43%), lifestyle changes (38%), dietary supplements (37%), counseling (27%), herbal medications (26%), megavitamins (24%), and prayer therapy (24%). One hundred forty-one patients (74%) used a protease inhibitor medication, 28 (15%) used a protease inhibitor sparing regime, and 22 (11%) had no current or prior antiretroviral use. Eighty-two (43%) patients indicated that their doctor knew they used CAM and 56 patients (29%) received their information about CAM from a doctor or other health care professional. Of 128 patients who used CAM, 90 (70%) felt CAM improved their quality of life. Income of $15,000 or more per year and discontinuation of medications by patients for any reason in the past were the best predicators of CAM use for patients in general and also those on protease inhibitor therapy. CD(4) count, educational status, year of HIV diagnosis, and martial status were not effective predictors of CAM use. Use of CAM remains widespread among patients with HIV infection even with the availability of effective, yet noncurative antiretroviral therapy and does not correlate with type of antiretroviral therapy used or clinical status.
Duggan
J
J
Department of Physiology and Molecular Medicine, Medical College of Ohio, Toledo, Ohio 43614-5804, USA. jduggan@mco.edu
Peterson
W S
WS
Schutz
M
M
Khuder
S
S
Charkraborty
J
J
D000328:Adult; D000553:Ambulatory Care / Q000706:statistics & numerical data; D019380:Anti-HIV Agents / Q000600:supply & distribution / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D000529:Complementary Therapies / Q000706:statistics & numerical data*; D004363:Drug Utilization; D004522:Educational Status; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000523:psychology* / Q000628:therapy*; D017320:HIV Protease Inhibitors / Q000600:supply & distribution / Q000627:therapeutic use; D006801:Humans; D007087:Illinois; D008297:Male; D009820:Ohio; D010342:Patient Acceptance of Health Care / Q000523:psychology* / Q000706:statistics & numerical data; D011237:Predictive Value of Tests; D011788:Quality of Life; D011795:Surveys and Questionnaires; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors